GETDex-ALL Study

Phase 1 study on the safety and pharmacokinetics of trametinib, gilteritinib or everolimus with dexamethasone in patients with relapsed or refractory acute B-lymphoblastic leukemia.


Dear Sir/Madam,

We warmly invite you to participate in an open, multicenter clinical trial aimed at evaluating the safety and pharmacokinetics, and determining the maximum tolerated and therapeutic dose of three kinase inhibitors: trametinib, gilteritinib or everolimus in combination with dexamethasone in adult oncology patients.

In case of technical problems, please contact:

BioStat Sp. z o.o.
ul. Kowalczyka 17, 44-206 Rybnik
tel: 666 069 834
email: [email protected]

Login to the eCRF system

BioStat eCRF